NCR2 and glioma: Similarly, IL-13 muteins have been engineered into CARs for selective targeting of IL13Rα2-expressing gliomas, while natural receptor ectodomains such as NKp30 or NKp44 have been incorporated to leverage endogenous NK recognition mechanisms [145,146,147].